Analytical Data
-
Gene name
Cxcl9
- Application
-
Alternative Names
Gamma-interferon-induced monokine;Monokine induced by interferon-gamma ;MIG ;MuMIGProtein m119Small-inducible cytokine B9
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P18340
-
Expression Region
22-126aa
-
Molecular Weight
16.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL9, also known as monokine induced by gamma interferon (MIG), is a chemokine that plays a crucial role in the immune response, particularly in T cell recruitment and activation. Its expression is primarily induced by interferon-gamma (IFN-γ), making it a significant player in various inflammatory conditions and diseases, including cancer, autoimmune disorders, and chronic infections. The study of recombinant CXCL9 protein has gained momentum due to its potential therapeutic applications. For instance, CXCL9 has been implicated in enhancing anti-tumor immunity by attracting effector T cells to the tumor microenvironment, thereby promoting tumor rejection. Additionally, CXCL9's role in the pathogenesis of autoimmune diseases offers insights into novel treatment options that leverage its signaling pathways. Research into the recombinant production of CXCL9 has focused on optimizing expression systems to yield biologically active protein, improving purification processes to ensure functional integrity, and exploring its interactions with receptors and other regulatory molecules in the immune system. Understanding the structure-function relationship of CXCL9 and its potential to modulate immune responses presents exciting opportunities for developing targeted therapies aimed at enhancing immune responses in cancer and managing chronic inflammatory diseases. As the field progresses, continued exploration of CXCL9's mechanisms and its therapeutic applications is expected to provide significant advancements in immunotherapy and precision medicine.
